Impact of inflammation on the osteoblast in rheumatic diseases

Current Osteoporosis Reports

Volumn 12, Issue 1, 2014, Pages 9-16

  Baum, Rebecca ^a   Gravallese, Ellen M ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Ankylosing spondylitis; Bone erosions; Bone formation; Bone remodeling; DKK1; Entheses; Inflammation; Osteoblast; Osteoclast; Rheumatoid arthritis; Sclerostin; Wnt

Indexed keywords

BONE MORPHOGENETIC PROTEIN; INTERLEUKIN 1; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 23; INTERLEUKIN 6; SCLEROSTIN; TUMOR NECROSIS FACTOR; WNT1 PROTEIN; WNT3A PROTEIN;

ANKYLOSING SPONDYLITIS; BMP SIGNALING PATHWAY; BONE EROSION; BONE REMODELING; FRACTURE HEALING; HUMAN; INFLAMMATION; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOLYSIS; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; WNT SIGNALING PATHWAY;

ARTHRITIS, RHEUMATOID; BONE REMODELING; BONE RESORPTION; CELL DIFFERENTIATION; CYTOKINES; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; OSTEOBLASTS; OSTEOCLASTS; SPONDYLITIS, ANKYLOSING;

EID: 84896796795     PISSN: 15441873     EISSN: 15442241     Source Type: Journal    
DOI: 10.1007/s11914-013-0183-y     Document Type: Review

References (80)

1. Sims NA, Gooi JH. Bone remodeling: multiple cellular interactions required for coupling of bone formation and resorption. Semin Cell Dev Biol. 2008;19:444-51.
2. Kular J et al. An overview of the regulation of bone remodelling at the cellular level. Clin Biochem. 2012;45:863-73.
3. Teitelbaum SL. Bone resorption by osteoclasts. Science. 2000;289:1504-8.
4. Matsuo K, Irie N. Osteoclast-osteoblast communication. Arch Biochem Biophys. 2008;473:201-9.
5. Hayden JM, Mohan S, Baylink DJ. The insulin-like growth factor system and the coupling of formation to resorption. Bone. 1995;17:93S-8S.
6. Tang Y et al. TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat Med. 2009;15:757-65.
7. Martin TJ et al. Communication between ephrinB2 and EphB4 within the osteoblast lineage. Adv Exp Med Biol. 2010;658:51-60.
8. Zhao C et al. Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis. Cell Metab. 2006;4:111-21. (Pubitemid 44138718)
9. Walker EC et al. Cardiotrophin-1 is an osteoclast-derived stimulus of bone formation required for normal bone remodeling. J Bone Miner Res. 2008;23:2025-32.
10. Pittenger MF et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284:143-7. (Pubitemid 29282067)
11. Komori T. Regulation of skeletal development by the Runx family of transcription factors. J Cell Biochem. 2005;95:445-53. (Pubitemid 41420175)
12. Biskobing DM, Fan X, Rubin J. Characterization of MCSF-induced proliferation and subsequent osteoclast formation in murine marrow culture. J Bone Miner Res. 1995;10:1025-32.
13. Takahashi N, Udagawa N, Suda T. A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function. Biochem Biophys Res Commun. 1999;256:449-55. (Pubitemid 29301126)
14. Yasuda H et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology. 1998;139:1329-37. (Pubitemid 28510154)
15. Ma YL et al. Catabolic effects of continuous human PTH (1-38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology. 2001;142:4047-54. (Pubitemid 32802678)
16. Blackwell KA, Raisz LG, Pilbeam CC. Prostaglandins in bone: bad cop, good cop? Trends Endocrinol Metab. 2010;21:294-301.
17. Huang H, He X. Wnt/beta-catenin signaling: new (and old) players and new insights. Curr Opin Cell Biol. 2008;20:119-25.
18. Regard JB, et al. Wnt signaling in bone development and disease: making stronger bone with Wnts. Cold Spring Harb Perspect Biol. 2012;4.
19. Monroe DG et al. Update on Wnt signaling in bone cell biology and bone disease. Gene. 2012;492:1-18.
20. Bodine PV et al. The Wnt antagonist secreted frizzled-related protein-1 controls osteoblast and osteocyte apoptosis. J Cell Biochem. 2005;96:1212-30. (Pubitemid 41681864)
21. Yao W et al. Overexpression of secreted frizzled-related protein 1 inhibits bone formation and attenuates parathyroid hormone bone anabolic effects. J Bone Miner Res. 2010;25:190-9.
22. Bodine PV et al. The Wnt antagonist secreted frizzled-related protein-1 is a negative regulator of trabecular bone formation in adult mice. Mol Endocrinol. 2004;18:1222-37. (Pubitemid 38591287)
23. Pinzone JJ et al. The role of Dickkopf-1 in bone development, homeostasis, and disease. Blood. 2009;113:517-25.
24. Morvan F et al. Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. J Bone Miner Res.2006;21:934-45. (Pubitemid 43788000)
25. Li J et al. Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. Bone. 2006;39:754-66. (Pubitemid 44311706)
26. Wang SY et al. Circulating Dickkopf-1 is correlated with bone erosion and inflammation in rheumatoid arthritis. J Rheumatol. 2011;38:821-7.
27. Heiland GR et al. High level of functional dickkopf-1 predicts protection from syndesmophyte formation in patients with ankylosing spondylitis. Ann Rheum Dis. 2012;71:572-4.
28. Li X et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem. 2005;280:19883-7. (Pubitemid 41379516)
29. Balemans W et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet. 2001;10:537-43.
30. van Lierop AH et al. Van Buchem disease: clinical, biochemical, and densitometric features of patients and disease carriers. J Bone Miner Res. 2013;28:848-54.
31. Hamersma H, Gardner J, Beighton P. The natural history of sclerosteosis. Clin Genet. 2003;63:192-7. (Pubitemid 36949919)
32. Li X et al. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res. 2008;23:860-9. (Pubitemid 351768804)
33. Winkler DG et al. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J. 2003;22:6267-76. (Pubitemid 37522584)
34. Costa AG, Bilezikian JP. Sclerostin: therapeutic horizons based upon its actions. Curr Osteoporos Rep. 2012;10:64-72.
35. Spatz JM et al. Sclerostin antibody inhibits skeletal deterioration due to reduced mechanical loading. J Bone Miner Res. 2013;28:865-74.
36. Li X et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res. 2009;24:578-88.
37. Padhi D et al. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res. 2011;26:19-26.
38. Chen G, Deng C, Li YP. TGF-beta and BMP signaling in osteoblast differentiation and bone formation. Int J Biol Sci. 2012;8:272-88.
39. Lories RJ, Derese I, Luyten FP. Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitis. J Clin Invest. 2005;115:1571-9. (Pubitemid 40814665)
40. Li P et al. Systemic tumor necrosis factor alphamediates an increase in peripheral CD11bhigh osteoclast precursors in tumor necrosis factor alpha-transgenic mice. Arthritis Rheum. 2004;50:265-76. (Pubitemid 38084312)
41. Kotake S et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest. 1999;103:1345-52. (Pubitemid 29218305)
42. Lam J et al. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest. 2000;106:1481-8. (Pubitemid 32038586)
43. Walsh NC, Gravallese EM. Bone remodeling in rheumatic disease: a question of balance. Immunol Rev. 2010;233:301-12.
44. Scott DL. Prognostic factors in early rheumatoid arthritis. Rheumatology. 2000;39:24-9. (Pubitemid 30352940)
45. Gravallese EM et al. Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am J Pathol. 1998;152:943-51. (Pubitemid 28173356)
46. Bromley M, Woolley DE. Chondroclasts and osteoclasts at subchondral sites of erosion in the rheumatoid joint. Arthritis Rheum. 1984;27:968-75. (Pubitemid 14004758)
47. Suzuki Y et al. Osteoclast-like cells in murine collagen induced arthritis. J Rheumatol. 1998;25:1154-60. (Pubitemid 28350891)
48. Romas E et al. Expression of osteoclast differentiation factor at sites of bone erosion in collagen-induced arthritis. Arthritis Rheum. 2000;43:821-6.
49. Kuratani T et al. Induction of abundant osteoclast-like multinucleated giant cells in adjuvant arthritic rats with accompanying disordered high bone turnover. Histol Histopathol. 1998;13:751-9. (Pubitemid 28329179)
50. Gravallese EM et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum. 2000;43:250-8. (Pubitemid 30395732)
51. Pettit AR et al. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol. 2001;159:1689-99. (Pubitemid 33062512)
52. Redlich K et al. Osteoclasts are essential for TNF-alpha-mediated joint destruction. J Clin Invest. 2002;110:1419-27. (Pubitemid 35396913)
53. Moller Dohn U et al. Erosive progression is minimal, but erosion healing rare, in patients with rheumatoid arthritis treated with adalimumab. A 1 year investigator-initiated follow-up study using high-resolution computed tomography as the primary outcome measure. Ann Rheum Dis. 2009;68:1585-90.
54. • Dohn UM et al. No overall progression and occasional repair of erosions despite persistent inflammation in adalimumab-treated rheumatoid arthritis patients: results from a longitudinal comparative MRI, ultrasonography, CT, and radiography study. Ann Rheum Dis. 2011;70:252-8.
55. Haavardsholm EA et al. Magnetic resonance imaging findings in 84 patients with early rheumatoid arthritis: bone marrow edema predicts erosive progression. Ann Rheum Dis. 2008;67:794-800. (Pubitemid 351843277)
56. Hetland ML et al. MRI bone edema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomized controlled trial (CIMESTRA). Ann Rheum Dis. 2009;68:384-90.
57. Gilbert L et al. Expression of the osteoblast differentiation factor RUNX2 (Cbfa1/AML3/Pebp2alpha A) is inhibited by tumor necrosis factor-alpha. J Biol Chem. 2002;277:2695-701. (Pubitemid 34953297)
58. Wei S et al. IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest. 2005;115:282-90. (Pubitemid 40385470)
59. Jilka RL et al. Osteoblast programmed cell death (apoptosis): modulation by growth factors and cytokines. J Bone Miner Res. 1998;13:793-802. (Pubitemid 28224195)
60. Stashenko P et al. Interleukin-1 beta is a potent inhibitor of bone formation in vitro. J Bone Miner Res. 1987;2:559-65.
61. Hengartner NE et al. IL-1beta inhibits human osteoblast migration. Mol Med. 2013;19:36-42.
62. Liu XH et al. Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system. Endocrinology. 2005;146:1991-8.
63. Walsh NC et al. Osteoblast function is compromised at sites of focal bone erosion in inflammatory arthritis. J Bone Miner Res. 2009;24:1572-85.
64. •• Matzelle MM et al. Resolution of inflammation induces osteoblast function and regulates the Wnt signaling pathway. Arthritis Rheum. 2012;64:1540-50.
65. Diarra D et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med. 2007;13:156-63.
66. Heiland GR et al. Neutralisation of Dkk-1 protects from systemic bone loss during inflammation and reduces sclerostin expression. Ann Rheum Dis. 2010;69:2152-9.
67. •• Chen XX et al. Sclerostin inhibition reverses systemic, periarticular and local bone loss in arthritis. Ann Rheum Dis. 2013;72:1732-6.
68. Finzel S et al. Repair of bone erosions in rheumatoid arthritis treated with tumour necrosis factor inhibitors is based on bone apposition at the base of the erosion. Ann Rheum Dis. 2011;70:1587-93.
69. •• Finzel S et al. Interleukin-6 receptor blockade induces limited repair of bone erosions in rheumatoid arthritis: a micro CT study. Ann Rheum Dis. 2013;72:396-400.
70. Lories RJ, Schett G. Pathophysiology of new bone formation and ankylosis in spondyloarthritis. Rheum Dis Clin North Am. 2012;38:555-67.
71. •• Uderhardt S et al. Blockade of Dickkopf (DKK)-1 induces fusion of sacroiliac joints. Ann Rheum Dis. 2010;69:592-7.
72. Haynes KR et al. Excessive bone formation in a mouse model of ankylosing spondylitis is associated with decreases in Wnt pathway inhibitors. Arthritis Res Ther. 2012;14:R253.
73. Appel H et al. Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum. 2009;60:3257-62.
74. Chen HA et al. Association of bone morphogenetic proteins with spinal fusion in ankylosing spondylitis. J Rheumatol. 2010;37:2126-32.
75. van der Heijde D et al. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res Ther. 2009;11:R127.
76. Schett G et al. Tumor necrosis factor alpha and RANKL blockade cannot halt bony spur formation in experimental inflammatory arthritis. Arthritis Rheum. 2009;60:2644-54.
77. Mei Y et al. Increased serum IL-17 and IL-23 in the patient with ankylosing spondylitis. Clin Rheumatol. 2011;30:269-73.
78. Duan Z et al. Interleukin-23 receptor genetic polymorphisms and ankylosing spondylitis susceptibility: a meta-analysis. Rheumatol Int. 2012;32:1209-14.
79. •• Sherlock JP et al. IL-23 induces spondyloarthropathy by acting on ROR-gammat+ CD3+CD4-CD8- entheseal resident T cells. Nat Med. 2012;18:1069-76.
80. Sherlock JP, Buckley CD, Cua DJ. The critical role of interleukin-23 in spondyloarthropathy. Mol Immunol. 2013;57:38-43.